Research Topics
Genomes and GenesSpecies | A Z DudekSummaryAffiliation: University of Minnesota Country: USA Publications
| Collaborators
|
Detail Information
Publications
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitorsArkadiusz Z Dudek
Masonic Cancer Center, University of Minnesota, Minneapolis, MN Electronic address
Clin Genitourin Cancer 11:155-60. 2013..The effectiveness of tyrosine kinase inhibitors (TKI) in preventing brain metastases in patients with renal cell carcinoma is unclear...
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief reportArkadiusz Z Dudek
Department of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA
J Thorac Oncol 7:755-9. 2012..We conducted a phase II trial of dasatinib in malignant mesothelioma (MM) patients to evaluate its toxicity and efficacy as a second-line treatment...
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapyHengbing Wang
Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
Anticancer Res 32:1027-31. 2012..This single-arm, phase II study was designed to determine the efficacy and safety of panobinostat and bortezomib in patients with advanced pancreatic cancer...- Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapyA Z Dudek
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA
Br J Cancer 97:513-22. 2007..These cells maintained an endothelial phenotype and decreased tumour vascularisation and tumour volume in mice. We conclude that BOECs have the potential for tumour-specific delivery of cancer gene therapy... - Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasisArkadiusz Z Dudek
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Invest New Drugs 26:13-24. 2008..We also show that the radiosensitizing effect of enzastaurin is associated with suppression of tumor cell proliferation and tumor-induced angiogenesis possibly through inhibition of the Ras pathway... - Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancerArkadiusz Z Dudek
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Am J Clin Oncol 30:481-6. 2007..0 was well tolerated on a biweekly schedule. Our findings indicate that further investigation of this biweekly regimen is warranted in patients with advanced cancer... - Carbonic anhydrase IX expression is associated with improved outcome of high-dose interleukin-2 therapy for metastatic renal cell carcinomaArkadiusz Z Dudek
Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, USA
Anticancer Res 30:987-92. 2010.... - Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancerArkadiusz Z Dudek
Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, MMC 286, 420 Delaware St S E, Minneapolis, MN, 55455, USA
Lung 183:43-52. 2005..After a median follow-up of 184 days, 13 patients died (76%). Median overall survival was 164 days. The combination of gemcitabine and vinorelbine has limited activity in relapsed SCLC... - Sequential therapy with sorafenib and sunitinib in renal cell carcinomaArkadiusz Z Dudek
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
Cancer 115:61-7. 2009..A retrospective study was conducted to assess the response of renal cell carcinoma to sequential treatment with these two agents... - Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancerArkadiusz Z Dudek
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
J Thorac Oncol 4:969-75. 2009..A secondary goal was to assay a panel of candidate serum biomarkers before and after neoadjuvant therapy... - Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptorA Z Dudek
Division of Hematology, Department of Medicine, Oncology and Transplantation, Comprehensive Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
Br J Cancer 100:1379-84. 2009..This combination therapy was moderately effective in extensively pretreated patients with non-small cell lung or head and neck cancers and warrants further investigation... - Safety of nab-paclitaxel plus sunitinib: analysis of three casesArkadiusz Z Dudek
Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Anticancer Res 28:3099-105. 2008..Second-line treatment options are limited in controlling advanced thoracic cancer in patients who have progressed following first-line chemotherapy... - Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinomaArkadiusz Z Dudek
Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware St SE, MMC 480, Minneapolis, MN 55455, USA
Am J Clin Oncol 31:173-81. 2008..To evaluate the safety and activity of large multivalent immunogen (LMI), prepared by immobilizing autologous tumor cell plasma membrane on 5-microm diameter silica beads, in patients with melanoma and renal cell carcinoma (RCC)... - Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapyArkadiusz Z Dudek
Division of Hematology, Oncologyand Transplantation, University of Minnesota Medical School, Minneapolis, MN 55455, USA
Transl Res 156:136-46. 2010.... - Polymorphisms in DNA repair gene XRCC1 and skin cancer risk: a meta-analysisHaijun Zhang
Department of Cell and Developmental Biology, Weill Medical College of Cornell University, New York, NY, USA
Anticancer Res 31:3945-52. 2011..In contrast, the Arg280His polymorphism was associated with an approximate 3.5-fold increase in skin cancer risk in homozygote codominant and recessive models... - Platelet factor 4 promotes adhesion of hematopoietic progenitor cells and binds IL-8: novel mechanisms for modulation of hematopoiesisArkadiusz Z Dudek
Department of Medicine, Division of Hematology, Oncology, and Transplantation, Stem Cell Institute, Minneapolis, MN, USA
Blood 101:4687-94. 2003.... - Molecular targets in the inhibition of angiogenesisArkadiusz Z Dudek
Division of Hematology, Oncology and Transplantation, Department of Medicine and Comprehensive Cancer Center, 420 Delaware Street, MMC 480, University of Minnesota, Minneapolis, MN 55455, USA
Expert Opin Ther Targets 7:527-41. 2003.... - Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomesArkadiusz Z Dudek
Bone Marrow Transplantation Program, University of Minnesota Health Sciences Center, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, USA
Biol Blood Marrow Transplant 9:657-66. 2003..BrOb had high mortality rate of 55%, and pulmonary failure was the leading cause of death. More effective BrOb therapy is needed, especially for patients with unfavorable presentation... - Neoadjuvant chemotherapy with reduced-dose carboplatin and gemcitabine for non-small cell lung cancer in a patient with Fanconi anemiaArkadiusz Z Dudek
Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical School, MMC 480, 420 Delaware St S E, Minneapolis, MN 55455, USA
J Thorac Oncol 3:447-50. 2008.... - Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survivalArkadiusz Z Dudek
Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
Cancer Invest 23:193-200. 2005..03). In NSCLC patients, VEGF levels are increased, whereas TSP1 levels are decreased, which may trigger and sustain tumor angiogenesis. High levels of serum VEGF at the time of presentation with NSCLC may predict worse survival... - Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancerArkadiusz Z Dudek
Division of Hematology, Oncology and Transplantation, University of Minnesota, MMC 480, 420 Delaware Street S E, Minneapolis, MN 55455, USA
Lung Cancer 51:89-96. 2006.... - Hematopoietic stem cell transplant-related airflow obstructionArkadiusz Z Dudek
Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, 55455, USA
Curr Opin Oncol 18:115-9. 2006..If airflow obstruction is consistent with obliteration histologically, the condition is often called bronchiolitis obliterans. This review of literature published recently evaluates progress made in this field... - Computational methods in developing quantitative structure-activity relationships (QSAR): a reviewArkadiusz Z Dudek
University of Minnesota Medical School, Minneapolis, 55455, USA
Comb Chem High Throughput Screen 9:213-28. 2006..We present both the well-established methods as well as techniques recently introduced into the QSAR domain... - Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancerArkadiusz Z Dudek
University of Minnesota Comprehensive Cancer Center, Minneapolis, Minnesota 55455, USA
J Thorac Oncol 3:394-9. 2008..Pemetrexed is synergistic with gemcitabine in preclinical models of non-small cell lung cancer (NSCLC). The optimal dose and utility of gemcitabine and pemetrexed was evaluated in a dose-escalating study... - Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell nicheP Gupta
Departments of Medicine, Biochemistry, and Orthopaedic Surgery, VA Medical Center, University of Minnesota Medical School, Minneapolis, MN, USA
Blood 92:4641-51. 1998..These findings may have important implications for ex vivo expansion of and gene transfer into primitive hematopoietic progenitors... - Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bonePawel Zwolak
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
Eur J Cancer 44:2506-17. 2008..Our study demonstrates that SU11248 enhances the radiation control of metastatic breast tumours in bone and tumour-induced pain... - Human LTC-IC can be maintained for at least 5 weeks in vitro when interleukin-3 and a single chemokine are combined with O-sulfated heparan sulfates: requirement for optimal binding interactions of heparan sulfate with early-acting cytokines and matrix prP Gupta
Department of Medicine, Veterans Affairs Medical Center Minneapolis, MN 55417, USA
Blood 95:147-55. 2000..Blood. 2000;95:147-155).. - Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumorsV Bodempudi
Division of Hematology, Oncology and Transplantation, Vascular Biology Center and Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
Cancer Gene Ther 17:855-63. 2010..0130). These results indicate that further research is warranted to develop BOECs for clinical application... - Pulmonary blastoma with renal metastasis responds to sorafenibKeerthi Mulamalla
Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA
J Thorac Oncol 2:344-7. 2007..We believe that further studies are warranted to confirm the possible effects of sorafenib on pulmonary blastomas... - Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastasesPawel Zwolak
Department of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Int J Cancer 122:681-8. 2008..We conclude that concurrent antiangiogenic therapy and localized radiotherapy for the treatment of bone metastases warrants further evaluation in human clinical trials... - Rare case of hemangiopericytoma responds to sunitinibKeerthi Mulamalla
Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
Transl Res 151:129-33. 2008..Additional studies are warranted to confirm the possible effects of sunitinib in controlling widespread metastatic HP... - Pericytes and vessel maturation during tumor angiogenesis and metastasisAhmad Raza
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
Am J Hematol 85:593-8. 2010..The purpose of this review is to evaluate critically recent evidence on the role of pericytes in tumor biology and discuss potential therapeutic targets for anticancer intervention... - Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature reviewPratima Kamada
Department of Oncology, and Transplantation, University of Minnesota, Minneapolis, USA
Cancer Invest 28:501-4. 2010..Sorafenib therapy resulted in disease stabilization of progressing RCC for both cases, without worsening of cardiac ejection fraction. Further evaluation of the cardiac safety of sorafenib in patients with cardiomyopathy is warranted... - Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastasesSteven Powell
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Anticancer Res 29:4189-93. 2009..High-dose interleukin-2 (HD IL-2) is known to produce durable responses in metastatic melanoma. The purpose of this study was to evaluate the response of metastatic melanoma to treatment with HD IL-2... - Review of selected patents for cancer therapy targeting tumor angiogenesisMark N Kirstein
Department of Experimental and Clinical Pharmacology, College of Pharmacy and Comprehensive Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
Recent Patents Anticancer Drug Discov 1:153-61. 2006.... - Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activityB J Stish
Department of Therapeutic Radiology Radiation Oncology, Section on Molecular Cancer Therapeutics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
Br J Cancer 101:1114-23. 2009..Potency, immunogenicity, and toxicity are three problems that limit the use of targeted toxins in solid tumour therapy... - Interleukin 2 in cancer therapyG K Antony
Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Curr Med Chem 17:3297-302. 2010..Here we discuss toxicity and established activity of IL-2 in the management of advanced malignancies, and speculate on future use of this cytokine for treatment of cancer... - Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantationJeffrey S Miller
Divisions of Medical and Pediatric Hematology Oncology and Transplantation, The Blood and Marrow Transplant Program, Department of Biostatistics, and The University of Minnesota Cancer Center, MN 55455, USA
Clin Immunol 117:144-51. 2005..KLH vaccines are safe and require only a single injection to test neo-antigen responses providing an optimal platform for definitive testing of strategies to improve diminished immune recovery after chemotherapy or post-HCT... - Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivoPiotr Jasinski
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minn 55455, USA
Transl Res 152:203-12. 2008..This quinoline, therefore, could potentially be active in Ras-mutated cancers and could be developed extensively as an anticancer molecule with this in mind... - Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural levelIrina V Nesmelova
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, Minnesota 55455, USA
J Biol Chem 280:4948-58. 2005..This concept, in turn, has implications for designing chemokine/cytokine variants with modified biological properties... - A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell linesPiotr Jasinski
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Invest New Drugs 26:223-32. 2008..We propose, therefore, that MT477 warrants further development as an anticancer drug... - Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase CPiotr Jasinski
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Eur J Cancer 44:1315-22. 2008..We conclude that enzastaurin has a radiosensitising effect on MCF-7 human xenograft tumours through the reversal of anti-apoptotic activation of PKC isoforms... - Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633Stephen L Graziano
Department of Medicine, State University of New York Upstate Medical University, Syracuse, New York 13210, USA
J Thorac Oncol 5:810-7. 2010..A laboratory companion study was conducted to see whether molecular and clinical factors could provide additional prognostic information... - Extension of survival by resection of asynchronous renal cell carcinoma metastases to mediastinal lymph nodesBryan A Whitson
Department of Surgery, University of Minnesota, Minneapolis, Minn 55455, USA
J Thorac Cardiovasc Surg 135:1022-8. 2008..The aim of this study was to determine whether or not resection of isolated mediastinal lymph node renal cell carcinoma metastases confers a survival advantage, as compared with patients with stage IV disease... - Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case reportAnu Dham
Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
J Thorac Oncol 3:94-7. 2008..We believe that further study of sunitinib and octreotide with the neoadjuvant intent of preparing tumors for resection is warranted as a strategy to improve curative management of neuroendocrine tumors... - SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasisMani Keshtgarpour
Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
Transl Res 149:103-6. 2007 - Skin ulcers in Klippel-Trenaunay syndrome respond to sunitinibSheila Nguyen
Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, MN, USA
Transl Res 151:194-6. 2008 - Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulinChereddy Subhadra
Division of Hematology, Oncology, and Transplantation CS, AZD, University of Minnesota, Minneapolis, Minnesota 55455, USA
J Neuroophthalmol 28:23-6. 2008..In this setting, IVIg therapy should be considered a viable treatment option... - Collision tumor versus multiphenotypic differentiation: a case of carcinoma with features of colonic and lung primary tumorsPradeep Murthaiah
Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC 480 Minneapolis, MN 55455, U S A
Anticancer Res 29:1495-7. 2009..Collision tumors need to be distinguished from tumors originating from a progenitor cell with potential for multiphenotypic differentiation... - First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancerArkadiusz Z Dudek
University of Minnesota Cancer Center, Minneapolis, Minnesota and 3M Pharmaceuticals, St Paul, Minnesota 55455, USA
Clin Cancer Res 13:7119-25. 2007..Our goal was to define the tolerated dose, pharmacokinetics, pharmacodynamics, and immunologic effects of 852A in humans... - Ral overactivation in malignant peripheral nerve sheath tumorsVidya Bodempudi
Department of Medicine, KUMC Molecular Medicine Laboratory, University of Kansas School of Medicine, 1000 Hixon, Mail Stop 4037, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
Mol Cell Biol 29:3964-74. 2009..We propose Ral overactivation as a novel cell signaling abnormality in MPNST that leads to important biological outcomes with translational ramifications... - Platelet factor 4 binds to glycanated forms of thrombomodulin and to protein C. A potential mechanism for enhancing generation of activated protein CA Z Dudek
Department of Internal Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA
J Biol Chem 272:31785-92. 1997..These interactions may enhance the affinity of the thrombin.thrombomodulin complex for protein C and thereby promote the generation of activated protein C... - A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinomaSeunguk Oh
Masonic Cancer Center, Section on Molecular Cancer Therapeutics, Department of Therapeutic Radiology Radiation Oncology, University of Minnesota, Minneapolis, Minnesota 55455, USA
Clin Cancer Res 15:6137-47. 2009..Our purpose was to reduce toxin immunogenicity using mutagenesis, measure the ability of mutated drug to elicit B-cell antitoxin antibody responses, and show that mutated drug was effective against systemic breast cancer in vivo... - MT477 acts in tumor cells as an AURKA inhibitor and strongly induces NRF-2 signalingPiotr Jasinski
Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
Anticancer Res 31:1181-7. 2011..The present study examined the expression levels of 10,000 genes and how they changed after MT477 treatment in three cancer cell lines: H226, MDA231 and MiaPaCa-2. Materials and Methods/.. - Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patientsVivek Thumbigere-Math
Division of Periodontology, University of Minnesota School of Dentistry, Minneapolis, MN 55455, USA
J Oral Maxillofac Surg 67:1904-13. 2009..To report the clinical features, risk factors, management, and treatment outcomes of nitrogen-containing bisphosphonate (n-BIS)-related osteonecrosis of the jaw (BRONJ)... - Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell linesPawel Zwolak
Department of Orthopaedic Surgery, University of Minnesota Medical School and Masonic Cancer Center, 2450 Riverside Avenue, R200, Minneapolis, MN 55454, USA
J Bone Joint Surg Am 92:162-8. 2010..The aim of this study was to analyze the elution dynamics of zoledronic acid release from acrylic bone cement and its in vitro antitumor efficacy... - Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanomaMalcolm S Mitchell
University of California, San Diego, School of Medicine and Cancer Center, San Diego, CA, USA
J Clin Oncol 25:2078-85. 2007..To compare the overall survival (OS) of patients with resected stage III melanoma administered active specific immunotherapy and low-dose interferon alfa-2b (IFN-alpha-2b) with the OS achieved using high-dose IFN-alpha-2b...